Company research
Coherus Oncology, Inc.
CIK 1512762Updated Sep 27, 2026
SecurityCHRS · NASDAQ · equity
Name history
Coherus BioSciences, Inc. · through May 28, 2025BioGenerics, Inc. · through Jan 3, 2012
CHRS price & chart
Loading TradingView…
NASDAQ:CHRS on TradingView ↗About the company
Coherus Oncology is a fully integrated commercial-stage innovative oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI® (toripalimab-tpzi), growing revenues and a promising proprietary pipeline that includes two mid-stage clinical candidates targeting liver, head and neck, colorectal and other gastrointestinal cancers. The Company’s strategy is to grow sales of LOQTORZI in nasopharyngeal carcinoma and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its partners, driving sales multiples and synergies from proprietary combinations.
In the news
Coherus Oncology to Report Second Quarter 2026 Financial Results on August 5, 2026 ↗
Recent filings
Other Events
Items 8.01, 9.01
424B5 filing
424B3 filing
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
Entry into a Material Definitive Agreement · Termination of a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
Items 1.01, 1.02, 2.03, 9.01
Show 5 more recent filings
S-8 filing
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Changes in Registrant's Certifying Accountant
Items 4.01, 9.01
4 filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 258,343,000Source | 448,533,000Source | 629,604,000Source | 480,847,000Source |
| Property, Plant and Equipment, NetUSD | 1,345,000Source | 2,837,000Source | 5,119,000Source | 8,754,000Source |
| GoodwillUSD | — | — | 943,000Source | 900,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | — | — | 71,673,000Source | 5,931,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 88,879,000Source | 125,987,000Source | 102,891,000Source | 63,547,000Source |
| Inventory, NetUSD | 3,172,000Source | 70,094,000Source | 62,605,000Source | 38,791,000Source |
| Assets, CurrentUSD | 206,706,000Source | 341,583,000Source | 475,631,000Source | 381,234,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 6,233,000Source | 11,532,000Source | 11,099,000Source | 22,918,000Source |
| Operating Lease, Right-of-Use AssetUSD | 2,953,000Source | 4,518,000Source | 5,912,000Source | 5,690,000Source |
| Other Assets, NoncurrentUSD | 4,053,000Source | 6,691,000Source | 9,686,000Source | 8,668,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 197,329,000Source | 580,523,000Source | 823,029,000Source | 618,265,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 12,000Source | 12,000Source | 11,000Source | 8,000Source |
| Additional Paid in CapitalUSD | 1,444,166,000Source | 1,419,266,000Source | 1,386,312,000Source | 1,204,431,000Source |
| Retained Earnings (Accumulated Deficit)USD | -1,382,969,000Source | -1,550,993,000Source | -1,579,500,000Source | -1,341,608,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -195,000Source | -275,000Source | -248,000Source | -249,000Source |
| Stockholders' Equity Attributable to ParentUSD | 61,014,000Source | -131,990,000Source | -193,425,000Source | -137,418,000Source |
| Liabilities and EquityUSD | 258,343,000Source | 448,533,000Source | 629,604,000Source | 480,847,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 140,386,000Source | 282,981,000Source | 331,771,000Source | 138,694,000Source |
| Operating Lease, Liability, CurrentUSD | 1,828,000Source | 1,691,000Source | 1,424,000Source | 3,127,000Source |
| Accounts Payable, CurrentUSD | 9,915,000Source | 28,456,000Source | 35,219,000Source | 11,526,000Source |
| Operating Lease, Liability, NoncurrentUSD | 1,457,000Source | 3,286,000Source | 4,977,000Source | 3,628,000Source |
| Deferred Income Tax Liabilities, NetUSD | 1,102,000Source | 1,102,000Source | 1,102,000Source | — |
| Other Liabilities, NoncurrentUSD | 18,435,000Source | 29,329,000Source | 12,561,000Source | 3,467,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 20,430,000Source | 60,288,000Source | 105,386,000Source | 50,097,000Source |
| Deferred Tax Liabilities, NetUSD | 1,102,000Source | 1,102,000Source | 1,102,000Source | 2,506,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | 168,024,000Source | 28,507,000Source | -237,892,000Source | -291,754,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 1,300,000Source | 1,800,000Source | 3,200,000Source | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 16,966,000Source | 27,802,000Source | 43,110,000Source | 50,737,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in InventoriesUSD | 17,108,000Source | 31,952,000Source | 46,734,000Source | 47,348,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | -380,000Source | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -138,513,000Source | -20,440,000Source | -174,884,000Source | -241,124,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 375,087,000Source | 230,321,000Source | 144,640,000Source | -166,850,000Source |
| Payments for (Proceeds from) Other Investing ActivitiesUSD | 342,000Source | -110,000Source | — | — |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | 286,000Source | 2,039,000Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 283,000Source | 2,476,000Source | 3,587,000Source | 3,744,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | -273,705,000Source | -186,974,000Source | 69,600,000Source | 54,326,000Source |
| Proceeds from (Payments for) Other Financing ActivitiesUSD | -832,000Source | -248,000Source | -1,034,000Source | -1,228,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -37,131,000Source | 22,907,000Source | 39,356,000Source | -353,648,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 89,119,000Source | 126,250,000Source | 103,343,000Source | 63,987,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 9,916,000Source | 25,376,000Source | 37,857,000Source | 34,878,000Source |
| Income Taxes Paid, NetUSD | 36,000Source | -114,000Source | -118,000Source | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 16,966,000Source | 27,802,000Source | 43,110,000Source | 50,737,000Source |
| Amortization of Intangible AssetsUSD | 2,600,000Source | 3,400,000Source | — | — |
| Debt Securities, Available-for-sale, Allowance for Credit Loss, Not Previously RecordedUSD | 0Source | 0Source | 0Source | 0Source |
| Gain (Loss) on Extinguishment of DebtUSD | 0Source | -12,630,000Source | — | -6,222,000Source |
| GoodwillUSD | — | — | 943,000Source | 900,000Source |
| Goodwill, Impairment LossUSD | — | — | 0Source | 0Source |
| Impairment of Intangible Assets (Excluding Goodwill)USD | — | — | 0Source | — |
| Impairment of Intangible Assets, Finite-livedUSD | 0Source | 0Source | 0Source | 0Source |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | -183,124,000Source | — | — | — |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | 351,148,000Source | — | — | — |
| Income Tax Expense (Benefit)USD | 0Source | — | -380,000Source | 0Source |
| Inventory Write-downUSD | — | 14,143,000Source | 52,595,000Source | 26,000,000Source |
| Investment Income, InterestUSD | 7,000,000Source | 4,500,000Source | 2,800,000Source | 1,900,000Source |
| Net Income (Loss) Attributable to ParentUSD | 168,024,000Source | 28,507,000Source | -237,892,000Source | -291,754,000Source |
| Other Nonoperating Income (Expense)USD | 7,011,000Source | 3,373,000Source | 5,469,000Source | 3,822,000Source |
| Proceeds from Stock Options ExercisedUSD | — | 291,000Source | 694,000Source | 691,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | 42,172,000Source | 266,960,000Source | 257,244,000Source | 211,042,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cost of RevenueUSD | 13,814,000Source | 117,553,000Source | 158,992,000Source | 70,083,000Source |
| Selling, General and Administrative ExpenseUSD | 100,604,000Source | 167,738,000Source | 192,015,000Source | 198,481,000Source |
| Operating Income (Loss)USD | -181,134,000Source | -111,667,000Source | -203,199,000Source | -256,880,000Source |
| Other Nonoperating Income (Expense)USD | 7,011,000Source | 3,373,000Source | 5,469,000Source | 3,822,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -183,124,000Source | 28,507,000Source | -238,272,000Source | -291,754,000Source |
| Income Tax Expense (Benefit)USD | 0Source | — | -380,000Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | 168,024,000Source | 28,507,000Source | -237,892,000Source | -291,754,000Source |
| Earnings Per Share, BasicUSD per share | 1.43Source | 0.25Source | -2.53Source | -3.76Source |
| Earnings Per Share, DilutedUSD per share | 1.43Source | 0.25Source | -2.53Source | -3.76Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 117,143,457Source | 114,553,537Source | 94,162,637Source | 77,630,020Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 117,143,457Source | 114,830,462Source | 94,162,637Source | 77,630,020Source |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 2,600,000Source | 3,400,000Source | — | — |
| Costs and ExpensesUSD | 223,306,000Source | 378,627,000Source | 460,443,000Source | 467,922,000Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | 3,924,000Source | 5,276,000Source | 3,791,000Source | 3,699,000Source |
| Goodwill, Impairment LossUSD | — | — | 0Source | 0Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -183,124,000Source | 28,507,000Source | -238,272,000Source | -291,746,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | -183,124,000Source | — | — | — |
| Income (Loss) from Continuing Operations, Per Basic ShareUSD per share | -1.56Source | — | — | — |
| Income (Loss) from Continuing Operations, Per Diluted ShareUSD per share | -1.56Source | — | — | — |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | 351,148,000Source | — | — | — |
| Interest ExpenseUSD | 9,001,000Source | 27,158,000Source | 40,542,000Source | 32,474,000Source |
| Interest Expense, DebtUSD | 5,100,000Source | — | — | — |
| Investment Income, InterestUSD | 7,000,000Source | 4,500,000Source | 2,800,000Source | 1,900,000Source |
| Marketing and Advertising ExpenseUSD | 6,600,000Source | 10,900,000Source | 10,900,000Source | 10,500,000Source |
| Research and Development ExpenseUSD | 108,888,000Source | 93,336,000Source | 109,436,000Source | 199,358,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | 42,172,000Source | 266,960,000Source | 257,244,000Source | 211,042,000Source |
Filing attachments
chrs-20260817xex99d1.htm · 8-K · 2026-08-17
EX-99.1 2 chrs-20260817xex99d1.htm EX-99.1 Exhibit 99.1 Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights - Entitles holders to receive net proceeds from sale of remaining Legacy Biosimilar Assets - - Completes transformation of Coherus Oncology into a fully integrated, innovative immuno-oncology company - REDWOOD CITY, Calif., August 17, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) (“Coherus”, “Coherus Oncology” or the “Company”) today a…
Read attachment ↗chrs-20260817xex99d2.htm · 8-K · 2026-08-17
EX-99.2 3 chrs-20260817xex99d2.htm EX-99.2 Exhibit 99.2 Coherus Oncology, Inc. Stockholder FAQ - CVR Dividend What was announced? Coherus Oncology announced a special dividend to its stockholders in the form of contingent value rights (“CVR”). Coherus Oncology stockholders will receive one (1) CVR for each one (1) share of Coherus Oncology common stock that they hold of record as of 5:00 p.m. Eastern time on September 30, 2026, which is the “Record Date” for the dividend. For example, i…
Read attachment ↗chrs-20260805xex99d1.htm · 8-K · 2026-08-05
EX-99.1 2 chrs-20260805xex99d1.htm EX-99.1 Exhibit 99.1 Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update - LOQTORZI® net revenue of $13.6 million in Q2 2026, up 15% over Q1 - - Clinical data continue to mature across programs with emerging evidence of activity with tagmokitug in head and neck cancer - - Projected October public disclosure of data sets with sufficient maturity - - Conference call today at 5:00 p.m. Eastern Daylight Time - REDWO…
Read attachment ↗chrs-20260511xex99d1.htm · 8-K · 2026-05-11
EX-99.1 2 chrs-20260511xex99d1.htm EX-99.1 Exhibit 99.1 Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update - LOQTORZI® net revenue of $11.8 million in Q1 2026 - - Patient accrual complete for 1L HCC Phase 2 randomized clinical trial for anti-IL27 casdozokitug, timing for data readouts tracking to projections - - Tagmokitug, CCR8 Treg depleter development expands with pharmacological and clinical program differentiation, including dose-responsive …
Read attachment ↗chrs-20260309xex99d1.htm · 8-K · 2026-03-09
EX-99.1 2 chrs-20260309xex99d1.htm EX-99.1 Exhibit 99.1 Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update - LOQTORZI® net revenue more than doubled to $40.8 million in 2025 from $19.1 million in 2024 - - Reduced secured and convertible debt by 90% from $480 million to $38.8 million over 2024-2025 - - $172.1 million in year ending cash, cash equivalents and marketable securities - - Conference call today at 4:30 p.m. Eastern Standar…
Read attachment ↗chrs-20260113xex99d1.htm · 8-K · 2026-01-13
EX-99.1 2 chrs-20260113xex99d1.htm EX-99.1 Exhibit 99.1 ©2026 Coherus Oncology, Inc. Coherus Oncology Value Proposition Shareholder Value Creation Focused on Drugs, Data and Deals 1 DRUGS DATA DEALS Tagmokitug anti-CCR8 cytolytic antibody Casdozokitug IL-27 antagonist Commercial Stage Clinical Stage Tagmokitug • HNSCC – Mid 2026 • GC, GEJ, EAC – Mid 2026 • CRC – H2 2026 • ESCC – H2 2026 • Additional indications starting in 2026 Casdozokitug • HCC – Mi…
Read attachment ↗